A method for treating a human infected with Aspergillus by using thymosin alpha 1 as an immuno-stimulator in activating dendritic cells. The method is particularly useful in preventing an infection by Aspergillus in an immuno-compromised host being treated with a bone marrow transplantation.
1. A method for treating an Aspergillus infection in a mammal infected with Aspergillus comprising administering to said mammal in need thereof a pharmaceutical composition comprising an antifungal effective amount of thymosin alpha 1 (TA1).
2. The method according to claim 1 , wherein said TA1 is administered at a dose sufficient to activate dendritic cells to produce Th1 cell promoting cytokines.
3. The method according to claim 1 , wherein said TA1 is administered at a dose of 200 to 400 micrograms/kg body weight/day.
4. The method according to claim 1 , wherein said mammal is immunocompromised.
5. The method according to claim 4 , wherein said mammal is a human.
6. The method according to claim 5 , wherein said human is a bone marrow transplantation recipient.
7. The method according to claim 5 , wherein said TA1 is administered to activate dendritic cells to produce Th1 cell promoting cytokines.
8. The method according to claim 5 , wherein said TA1 is administered at a dose of 200 to 400 micrograms/kg body weight/day.
9. The method according to claim 1 , wherein the method further comprises administering to said mammal at least one additional antifungal agent.
10. The method according to claim 9 , wherein the additional antifungal agent is Amphotericin B.
11. The method according to claim 10 , wherein said Amphotericin B is administered at a dose of 4000 micrograms/kg body weight/day.
12. The method of claim 1 wherein said Aspergillus infection is Invasive Aspergillosis.